SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $386,614 | -72.0% | 14,023 | -69.4% | 0.00% | -66.7% |
| Q2 2023 | $1,379,754 | -22.5% | 45,900 | -6.6% | 0.00% | -25.0% |
| Q1 2023 | $1,781,067 | -24.8% | 49,160 | -26.0% | 0.00% | -33.3% |
| Q4 2022 | $2,369,202 | -5.9% | 66,420 | -10.7% | 0.01% | 0.0% |
| Q3 2022 | $2,517,000 | +221.9% | 74,370 | +175.1% | 0.01% | +200.0% |
| Q2 2022 | $782,000 | -72.4% | 27,038 | -69.2% | 0.00% | -60.0% |
| Q1 2022 | $2,835,000 | -0.6% | 87,722 | -10.3% | 0.01% | 0.0% |
| Q4 2021 | $2,852,000 | +14.0% | 97,789 | +4.3% | 0.01% | 0.0% |
| Q3 2021 | $2,501,000 | -13.4% | 93,792 | 0.0% | 0.01% | 0.0% |
| Q2 2021 | $2,888,000 | +12.3% | 93,792 | -4.5% | 0.01% | 0.0% |
| Q1 2021 | $2,572,000 | +11.3% | 98,252 | +7.0% | 0.01% | 0.0% |
| Q4 2020 | $2,310,000 | +114.1% | 91,812 | +77.3% | 0.01% | +150.0% |
| Q3 2020 | $1,079,000 | +16.5% | 51,771 | +32.7% | 0.00% | 0.0% |
| Q2 2020 | $926,000 | +100.4% | 39,002 | +51.7% | 0.00% | +100.0% |
| Q1 2020 | $462,000 | -72.2% | 25,706 | -63.3% | 0.00% | -75.0% |
| Q4 2019 | $1,663,000 | -13.8% | 70,106 | -0.2% | 0.00% | -20.0% |
| Q3 2019 | $1,930,000 | -18.3% | 70,246 | -1.6% | 0.01% | -16.7% |
| Q2 2019 | $2,361,000 | -5.4% | 71,363 | +0.2% | 0.01% | -14.3% |
| Q1 2019 | $2,496,000 | +20.8% | 71,223 | +14.5% | 0.01% | +16.7% |
| Q4 2018 | $2,067,000 | -36.5% | 62,212 | -3.8% | 0.01% | -25.0% |
| Q3 2018 | $3,257,000 | -7.6% | 64,678 | +9.8% | 0.01% | -11.1% |
| Q2 2018 | $3,525,000 | +206.3% | 58,900 | +134.3% | 0.01% | +200.0% |
| Q1 2018 | $1,151,000 | +18.1% | 25,136 | +2.8% | 0.00% | 0.0% |
| Q4 2017 | $975,000 | +3.0% | 24,457 | +3.3% | 0.00% | 0.0% |
| Q3 2017 | $947,000 | -7.2% | 23,677 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $1,020,000 | +41.7% | 23,677 | +2.9% | 0.00% | +50.0% |
| Q1 2017 | $720,000 | +23.9% | 23,006 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $581,000 | +2.1% | 23,006 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $569,000 | +20.6% | 23,006 | -0.7% | 0.00% | +100.0% |
| Q2 2016 | $472,000 | +54.2% | 23,176 | +15.3% | 0.00% | 0.0% |
| Q1 2016 | $306,000 | +13.3% | 20,094 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $270,000 | -75.2% | 20,094 | -74.1% | 0.00% | -75.0% |
| Q3 2015 | $1,088,000 | -32.8% | 77,531 | -18.7% | 0.00% | -33.3% |
| Q2 2015 | $1,618,000 | +196.9% | 95,312 | +111.3% | 0.01% | +200.0% |
| Q1 2015 | $545,000 | +240.6% | 45,111 | +133.6% | 0.00% | +100.0% |
| Q4 2014 | $160,000 | -4.8% | 19,312 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $168,000 | -20.4% | 19,312 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $211,000 | +51.8% | 19,312 | +24.5% | 0.00% | – |
| Q1 2014 | $139,000 | +18.8% | 15,513 | 0.0% | 0.00% | – |
| Q4 2013 | $117,000 | +2.6% | 15,513 | 0.0% | 0.00% | – |
| Q3 2013 | $114,000 | +14.0% | 15,513 | 0.0% | 0.00% | – |
| Q2 2013 | $100,000 | – | 15,513 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 335,000 | $8,934,000 | 13.38% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,016,665 | $27,114,000 | 2.46% |
| Bruce & Co., Inc. | 402,105 | $10,724,000 | 2.28% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $7,934,000 | 1.91% |
| ARMISTICE CAPITAL, LLC | 3,900,000 | $104,013,000 | 1.76% |
| Bridge City Capital, LLC | 108,884 | $2,904,000 | 1.32% |
| S&T BANK/PA | 316,098 | $8,430,000 | 1.31% |
| Kent Lake Capital LLC | 100,000 | $2,667,000 | 1.15% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 331,140 | $8,832,000 | 1.02% |
| Prairiewood Capital, LLC | 45,297 | $1,208,000 | 0.99% |